Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The deal is expected to close in early 2025 if antitrust authorities and other regulators sign off.

Cigna Sells Medicare Business for $3.3 Billion

Cigna's (CI) fourth-quarter results are likely to reflect growth in Evernorth revenues and customer base.

Cigna (CI) to Report Q4 Earnings: Can Rising Expenses Hurt?

Beyond analysts' top -and-bottom-line estimates for Cigna (CI), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Curious about Cigna (CI) Q4 Performance? Explore Wall Street Estimates for Key Metrics

American Financial Group

American Financial Group Inc 6 1/4 % Debentures 2014-30.9.54 Subord

Apollo Global Management

F&G Annuities & Life Inc

Fidelity National Financial

Legal & General Group PLC

Progressive

UnitedHealth Group

Trisura, Progressive, Cigna, UnitedHealth, Fidelity National, American Financial Group, Legal & General, and F&G Annuities & Life are highlighted as promising insurance picks with unique qualities.

My Top Insurance Picks In Early 2024

Cigna's subsidiary Evernorth is driving innovation and growth in the healthcare sector, positioning the company for potential success. The surge in Obamacare enrollments is a tailwind for Cigna, indicating an expanding customer base and opportunities for increased market share. Cigna's strategic decisions, such as offloading its Medicare Advantage business, demonstrate a commitment to growth and long-term sustainability.

Cigna Q4 Preview: The Analysts' Whisper - Deciphering Cigna's Next Big Leap

Apple

Abbott Labs

Best Buy

Microsoft

ReWalk Robotics

Teladoc

While it doesn't seem like it when you're young, aging happens to everyone and therefore, so-called AgeTech stocks should benefit from inevitability. A buzzword for age-related technology, this concept refers to a rapidly growing field focused on developing and applying innovative solutions to improve the lives of senior citizens.

7 ‘AgeTech' Stocks to Profit From the Booming Longevity Market

Amgen

Elevance Health Inc

Humana

Incyte

Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp. NASDAQ: PODD and Cigna Group NYSE: CI.

5 top healthcare stocks for earnings growth in 2024

Assurant

Ares Management

Broadcom

Costco

Comfort Systems USA

W.W. Grainger

Intercontinental Exchange

Intuit

JPMorgan Chase & Co

Lennox International

Mastercard

Martin Marietta Materials

NRG Energy

Owens Corning

Old Dominion Freight Line

PACCAR

Parker-Hannifin

PulteGroup

Vanguard Dividend Appreciation ETF

Wingstop

This article focuses on selecting high-growth dividend stocks that have rapidly grown their dividends in the recent past rather than simply sport a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks. It offers a step-by-step guide on structuring a portfolio based on this strategy.

Our Top 10 Dividend Growth Stocks - January 2024

Cigna Group should not be overlooked despite its short dividend growth streak, as its business model has proven successful and it benefits from aging demographics and growing demand for healthcare plans. The company has shown double-digit growth rates in revenue, net income, and earnings-per-share, and has a safe and growing dividend with a low payout ratio. Cigna's most recent financial results have exceeded expectations, and it has raised its guidance for FY2023, indicating continued growth and profitability.

Why Dividend Growth Investors Should Buy Cigna

CVS Health

A sharp spike in hospital and doctor office visits among older Americans is raising questions about the program.

Humana and Other Insurers Bet Big on Medicare Advantage. Now the Risks Are Coming Into Focus.

Brian Evanko to continue as Chief Financial Officer, will serve as new President and CEO of Cigna Healthcare Ann Dennison to join The Cigna Group as Deputy Chief Financial Officer Mike Triplett to retire by end of 2024 and Bryan Holgerson promoted to President of U.S. Commercial for Cigna Healthcare Eric Palmer to assume expanded role leading enterprise strategy and corporate development, will continue as President and CEO of Evernorth Health Services BLOOMFIELD, Conn. , Jan. 17, 2024 /PRNewswire/ -- The Cigna Group (NYSE: CI), a global health company, today announced leadership changes designed to continue accelerating growth across Evernorth Health Services and Cigna Healthcare.

The Cigna Group announces leadership changes to continue driving growth

BLOOMFIELD, Conn. , Jan. 11, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its fourth quarter 2023 financial results on Friday, February 2, 2024, and will host a conference call the same day.

The Cigna Group's Fourth Quarter 2023 Earnings Release Details

Here is how Cigna (CI) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Cigna Group (CI) This Year?

The Cigna Group (CI) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript

Insulet

Health Care Select Sector SPDR Fund

Zoetis

Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.

Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024

Cigna (CI) closed the most recent trading day at $313.63, moving +0.01% from the previous trading session.

Cigna (CI) Ascends But Remains Behind Market: Some Facts to Note

Cigna's (CI) Medicare Advantage unit's divestment is expected to fetch around $3-$4 billion.

Is Cigna (CI) Nearing a Medicare Advantage Divestment Deal?

Cigna Group (NYSE: CI) is now in advanced talks to sell its Medicare Advantage unit to Healthcare Services Group Inc (NASDAQ: HCSG). Its shares are down more than 1.0% at writing.

Cigna is close to a $4.0 billion deal to sell its Medicare Advantage unit

Health insurer Cigna Group is in exclusive talks to sell its Medicare Advantage business to Health Care Service Corp for between $3 billion and $4 billion, a source familiar with the matter said on Wednesday.

Cigna nears deal to offload Medicare business for up to $4 bln - source

Shares of Cigna Group CI, -1.92% shed 1.6% in morning trading, after The Wall Street Journal reported that the health insurer was in advanced talks to sell its Medicare business. Citing people familiar with the matter, the report said a sale of the Medicare Advantage business to Health Care Service Corp. could be for between $3 billion and $4 billion.

Cigna's stock drops after WSJ report the insurer was in talks to sell its Medicare business

The insurance giant is in exclusive talks to sell the unit to Health Care Service Corp. for between $3 billion and $4 billion.

Cigna Nears Deal to Offload Medicare Business

Domino's Pizza

EOG Resources

Microchip Technology

MarketAxess Holdings

MSCI

NIKE

Rollins

Sirius XM Holdings Inc

SPDR S&P 500 ETF Trust

SS&C Technologies Hlds

The SPDR S&P 500 ETF was up 4.57% in December, Vanguard's Dividend Appreciation ETF was up 4.13%, and my watchlist beat both with a return of 9.52%.

My Top 15 High Growth Dividend Stocks For January 2024

News for Cigna Stock (CI)